Literature DB >> 21411203

Design considerations and feasibility for a clinical trial to examine coronary screening before kidney transplantation (COST).

Bertram L Kasiske1, Ajay K Israni, Jon J Snyder, Alexa Camarena.   

Abstract

BACKGROUND: It is unclear whether benefits outweigh harms for routine screening and prophylactic revascularization to prevent coronary artery disease (CAD) in asymptomatic kidney transplant candidates. STUDY
DESIGN: Pilot feasibility study with prospective observational data collection and patient interviews. SETTING & PARTICIPANTS: Consecutive patients referred for kidney and/or pancreas transplant at 26 major transplant centers in the United States. PREDICTORS: Older age, diabetes, prior cardiovascular disease, and multiple traditional CAD risk factors. OUTCOMES: Eligibility and willingness to participate in a randomized controlled trial (RCT) to study the effect of CAD screening on major adverse cardiac events. MEASUREMENTS: Patients who would be candidates for a hypothetical RCT of CAD screening were interviewed and asked if they would participate in such a trial. Sample size for the trial was estimated using data for Medicare patients in the US Renal Data System with major adverse cardiac events as the primary end point.
RESULTS: Of consecutive eligible patients, CAD evaluation was not indicated in 398 (24%), already completed before referral in 602 (36%), and pending (and hence eligible for an RCT) in 665 (40%). Of 241 interviewed, 73% indicated they would be willing to participate in an RCT. We estimated that ~4,000 would need to be enrolled to detect a 20% decrease in major adverse cardiac events at >80% power at P < 0.05. LIMITATIONS: Willingness to participate in an actual clinical trial may be different from indicated in an interview.
CONCLUSION: An RCT to compare the effects of routine screening for CAD versus no screening on major adverse cardiac events is feasible.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21411203      PMCID: PMC3587732          DOI: 10.1053/j.ajkd.2011.01.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control?

Authors:  Don Poldermans; Jeroen J Bax; Olaf Schouten; Aleksandar N Neskovic; Bernard Paelinck; Guido Rocci; Laura van Dortmont; Anai E S Durazzo; Louis L M van de Ven; Marc R H M van Sambeek; Miklos D Kertai; Eric Boersma
Journal:  J Am Coll Cardiol       Date:  2006-08-17       Impact factor: 24.094

3.  Coronary-artery revascularization before elective major vascular surgery.

Authors:  Edward O McFalls; Herbert B Ward; Thomas E Moritz; Steven Goldman; William C Krupski; Fred Littooy; Gordon Pierpont; Steve Santilli; Joseph Rapp; Brack Hattler; Kendrick Shunk; Connie Jaenicke; Lizy Thottapurathu; Nancy Ellis; Domenic J Reda; William G Henderson
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

4.  Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation.

Authors:  Gabriel M Danovitch; Sundaram Hariharan; John D Pirsch; David Rush; David Roth; Emilio Ramos; Randall C Starling; Chuck Cangro; Mattthew R Weir
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

5.  Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.

Authors:  Ravinder K Wali; Gregory S Wang; Stephen S Gottlieb; Lavanya Bellumkonda; Riple Hansalia; Emilio Ramos; Cinthia Drachenberg; John Papadimitriou; Meredith A Brisco; Steve Blahut; Jeffrey C Fink; Michael L Fisher; Stephen T Bartlett; Matthew R Weir
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

6.  Acute myocardial infarction and kidney transplantation.

Authors:  Bertram L Kasiske; J Ross Maclean; Jon J Snyder
Journal:  J Am Soc Nephrol       Date:  2006-02-15       Impact factor: 10.121

7.  The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers.

Authors:  E L Ramos; B L Kasiske; S R Alexander; G M Danovitch; W E Harmon; L Kahana; T J Kiresuk; J F Neylan
Journal:  Transplantation       Date:  1994-02-27       Impact factor: 4.939

8.  European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.1. Cardiovascular risks. Cardiovascular disease after renal transplantation.

Authors: 
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

9.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

Authors:  Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Authors:  Andrew G Bostom; Myra A Carpenter; Lawrence Hunsicker; Paul F Jacques; John W Kusek; Andrew S Levey; Joyce L McKenney; Renee Y Mercier; Marc A Pfeffer; Jacob Selhub
Journal:  Am J Kidney Dis       Date:  2008-11-20       Impact factor: 8.860

View more
  6 in total

1.  Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Authors:  D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

2.  Propensity Score and Instrumental Variable Techniques in Observational Transplantation Studies: An Overview and Worked Example Relating to Pre-Transplant Cardiac Screening.

Authors:  Ailish Nimmo; Nicholas Latimer; Gabriel C Oniscu; Rommel Ravanan; Dominic M Taylor; James Fotheringham
Journal:  Transpl Int       Date:  2022-06-27       Impact factor: 3.842

3.  Risk-stratified cardiovascular screening including angiographic and procedural outcomes of percutaneous coronary interventions in renal transplant candidates.

Authors:  Julian König; Martin Möckel; Eda Mueller; Wolfgang Bocksch; Seema Baid-Agrawal; Nina Babel; Ralf Schindler; Petra Reinke; Peter Nickel
Journal:  J Transplant       Date:  2014-06-19

4.  Serum miR-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention.

Authors:  Tao Chen; Xueshan Zhang; Wei Qian; Ran Zhou; Mingyu Su; Yanfeng Ma
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant.

Authors:  Jose Jg De Lima; Luis Henrique W Gowdak; Flavio J de Paula
Journal:  Transplant Res       Date:  2012-04-24

6.  KNOW-KT (KoreaN cohort study for outcome in patients with kidney transplantation: a 9-year longitudinal cohort study): study rationale and methodology.

Authors:  Jaeseok Yang; Joongyup Lee; Kyu Ha Huh; Jae Berm Park; Jang-Hee Cho; Sik Lee; Han Ro; Seung-Yeup Han; Young Hoon Kim; Jong Cheol Jeong; Byung-Joo Park; Duck Jong Han; Sung-Bae Park; Wookyung Chung; Sung Kwang Park; Chan-Duck Kim; Sung Joo Kim; Yu Seun Kim; Curie Ahn
Journal:  BMC Nephrol       Date:  2014-05-09       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.